{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T18:00:33Z","timestamp":1783792833613,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"DOI":"10.1186\/s41927-025-00510-1","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T03:08:54Z","timestamp":1748315334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world evidence of biological treatments in rheumatoid arthritis and spondyloarthritis in Morocco: results of the RBSMR registry"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1228-391X","authenticated-orcid":false,"given":"Najlae","family":"El Ouardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4402-5034","authenticated-orcid":false,"given":"Ihsane","family":"Hmamouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Redouane","family":"Abouqal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadoua","family":"Allali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Bahiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imane","family":"El Bouchti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7966-4173","authenticated-orcid":false,"given":"Imad","family":"Ghozlani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasna","family":"Hassikou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2733-5594","authenticated-orcid":false,"given":"Linda","family":"Ichchou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadia","family":"Janani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taoufik","family":"Harzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0472-2532","authenticated-orcid":false,"given":"Radouane","family":"Niamane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3788-7146","authenticated-orcid":false,"given":"Ahmed","family":"Bezza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0668-5680","authenticated-orcid":false,"given":"Abdellah","family":"El Maghraoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"510_CR1","first-page":"1487","volume":"126","author":"L Virkki","year":"2010","unstructured":"Virkki L, Aaltonen K, Nordstr\u00f6m D. [Biological therapy in rheumatoid arthritis based on ten years of registry surveillance in Finland]. Duodecim. 2010;126:1487\u201395.","journal-title":"Duodecim"},{"key":"510_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.rdc.2022.03.005","volume":"48","author":"JA Singh","year":"2022","unstructured":"Singh JA. Treatment guidelines in rheumatoid arthritis. Rheum Dis Clin North Am. 2022;48:679\u201389.","journal-title":"Rheum Dis Clin North Am"},{"key":"510_CR3","doi-asserted-by":"publisher","first-page":"VI12","DOI":"10.1093\/rheumatology\/keab609","volume":"60","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y. Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs. Rheumatology (Oxford). 2021;60:VI12\u201320.","journal-title":"Rheumatology (Oxford)"},{"key":"510_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41584-022-00761-z","volume":"18","author":"A Danve","year":"2022","unstructured":"Danve A, Deodhar A. Treatment of axial spondyloarthritis: an update. Nat Rev Rheumatol. 2022;18:205\u201316.","journal-title":"Nat Rev Rheumatol"},{"key":"510_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.rbr.2014.06.006","volume":"55","author":"LMH da Mota","year":"2015","unstructured":"da Mota LMH, Cruz BA, Brenol CV, et al. Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides. Revista Brasileira De Reumatologia (English Edition). 2015;55:281\u2013309.","journal-title":"Revista Brasileira De Reumatologia (English Edition)"},{"key":"510_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/RHU.0000000000000935","volume":"26","author":"M Cecconi","year":"2020","unstructured":"Cecconi M, Ranza R, Titton DC, et al. Incidence of infectious adverse events in patients with rheumatoid arthritis and spondyloarthritis on biologic Drugs\u2014Data from the Brazilian registry for biologics monitoring. J Clin Rheumatol. 2020;26:73.","journal-title":"J Clin Rheumatol"},{"key":"510_CR7","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1517\/14712598.2014.967211","volume":"14","author":"RJ Lories","year":"2014","unstructured":"Lories RJ, De Vlam K. Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: A view on effectiveness, clinical practice and toxicity. Expert Opin Biol Ther. 2014;14:1825\u201336.","journal-title":"Expert Opin Biol Ther"},{"key":"510_CR8","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/acr.22645","volume":"67","author":"A Kavanaugh","year":"2015","unstructured":"Kavanaugh A, Puig L, Gottlieb AB, et al. Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, Placebo-Controlled phase III trial. Arthritis Care Res (Hoboken). 2015;67:1739\u201349.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"510_CR9","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137\u201346.","journal-title":"Lancet"},{"key":"510_CR10","doi-asserted-by":"publisher","unstructured":"Colombo D, Frassi M, Pagano Mariano G et al. Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic treatments for psoriatic artHRitis in Italy: an ObservatioNal lOngitudinal Study of real-life clinical practice) observational longitudinal study. BMC Rheumatol; 6. Epub ahead of print 1 December 2022. https:\/\/doi.org\/10.1186\/s41927-022-00284-w","DOI":"10.1186\/s41927-022-00284-w"},{"key":"510_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00296-022-05237-7","volume":"43","author":"N El Ouardi","year":"2023","unstructured":"El Ouardi N, El Maghraoui A, Djossou HJ, et al. Discontinuation of biologic therapy in patients with rheumatoid arthritis and ankylosing spondylitis: analysis from multicenter cohort study. Rheumatol Int. 2023;43:79\u201387. https:\/\/doi.org\/10.1007\/s00296-022-05237-7.","journal-title":"Rheumatol Int"},{"key":"510_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.24398\/A.344.2019","volume":"49","author":"I Hmamouchi","year":"2019","unstructured":"Hmamouchi I, Abouqal R, Achemlal L, et al. The Moroccan registry of biological therapies in rheumatic diseases (RBSMR): methods and preliminaries results. Revue Marocaine De Rhumatologie Rev Mar Rhum. 2019;49:32\u20137. https:\/\/doi.org\/10.24398\/A.344.2019.","journal-title":"Revue Marocaine De Rhumatologie Rev Mar Rhum"},{"key":"510_CR13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/ard.2011.149765","volume":"70","author":"DT Felson","year":"2011","unstructured":"Felson DT, Smolen JS, Wells G, et al. American college of rheumatology\/european league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70:404\u201313.","journal-title":"Ann Rheum Dis"},{"key":"510_CR14","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1136\/annrheumdis-2018-213184","volume":"77","author":"PM Machado","year":"2018","unstructured":"Machado PM, Landew\u00e9 R, van der Heijde D. Ankylosing spondylitis disease activity score (ASDAS): 2018 update of the nomenclature for disease activity States. Ann Rheum Dis. 2018;77:1539\u201340.","journal-title":"Ann Rheum Dis"},{"key":"510_CR15","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.rdc.2009.10.001","volume":"35","author":"J Fransen","year":"2009","unstructured":"Fransen J, van Riel PLCM. The disease activity score and the EULAR response criteria. Rheumatic Disease Clin North Am. 2009;35:745\u201357.","journal-title":"Rheumatic Disease Clin North Am"},{"key":"510_CR16","unstructured":"Braun J, Pham T, Sieper J et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis, www.annrheumdis.com"},{"key":"510_CR17","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1136\/ard.2009.118935","volume":"69","author":"WG Dixon","year":"2010","unstructured":"Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British society for rheumatology biologics register (BSRBR). Ann Rheum Dis. 2010;69:522\u20138.","journal-title":"Ann Rheum Dis"},{"key":"510_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jbspin.2016.02.028","volume":"84","author":"M de La Forest Divonne","year":"2017","unstructured":"de La Forest Divonne M, Gottenberg JE, Salliot C. Safety of biologic DMARDs in RA patients in real life: A systematic literature review and meta-analyses of biologic registers. Joint Bone Spine. 2017;84:133\u201340.","journal-title":"Joint Bone Spine"},{"key":"510_CR19","doi-asserted-by":"publisher","unstructured":"Koh JH, Lee Y, Kim HA et al. Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry. Ther Adv Musculoskelet Dis; 14. Epub ahead of print 2022. https:\/\/doi.org\/10.1177\/1759720X221096363","DOI":"10.1177\/1759720X221096363"},{"key":"510_CR20","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1093\/rheumatology\/keab565","volume":"61","author":"LP Vegas","year":"2022","unstructured":"Vegas LP, Sbidian E, Wendling D, et al. Factors associated with remission at 5-year follow-up in recent-onset axial spondyloarthritis: results from the DESIR cohort. Rheumatology (Oxford). 2022;61:1487\u201395.","journal-title":"Rheumatology (Oxford)"},{"key":"510_CR21","doi-asserted-by":"publisher","first-page":"448","DOI":"10.31138\/mjr.090723.pof","volume":"35","author":"S Boussaid","year":"2024","unstructured":"Boussaid S, Tbini H, Rekik S, et al. Predictors of drug retention and survival rate of bDMARDs in rheumatoid arthritis: A Four-Year Real-Life Tunisian experience. Mediterr J Rheumatol. 2024;35:448\u201358. https:\/\/doi.org\/10.31138\/mjr.090723.pof.","journal-title":"Mediterr J Rheumatol"},{"key":"510_CR22","doi-asserted-by":"publisher","unstructured":"Yazici A, \u00d6zdemir I\u015f\u0131k \u00d6, Dalk\u0131l\u0131\u00e7 E et al. A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry. Sci Rep; 12. Epub ahead of print 1 December 2022. https:\/\/doi.org\/10.1038\/S41598-022-26106-0","DOI":"10.1038\/S41598-022-26106-0"},{"key":"510_CR23","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1093\/rheumatology\/keac174","volume":"61","author":"M Nissen","year":"2022","unstructured":"Nissen M, Delcoigne B, Di Giuseppe D, et al. The impact of a CsDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis. Rheumatology (Oxford). 2022;61:4741\u201351.","journal-title":"Rheumatology (Oxford)"},{"key":"510_CR24","doi-asserted-by":"publisher","unstructured":"Al-Saleh JA, Saab MA, Negm A et al. Predictors of not Achieving Remission or Low Disease Activity in Axial Spondyloarthritis Patients from Middle Eastern Countries: A Prospective, Multicenter, Real-world Study. Oman Med J; 37. Epub ahead of print 1 May 2022. https:\/\/doi.org\/10.5001\/omj.2022.69","DOI":"10.5001\/omj.2022.69"},{"key":"510_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","volume":"15","author":"S Minozzi","year":"2016","unstructured":"Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15:11\u201334.","journal-title":"Expert Opin Drug Saf"},{"key":"510_CR26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.berh.2015.05.009","volume":"29","author":"M Lahiri","year":"2015","unstructured":"Lahiri M, Dixon WG. Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2015;29:290\u2013305.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"510_CR27","doi-asserted-by":"publisher","unstructured":"Fragoulis GE, Dey M, Zhao S et al. Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. RMD Open; 8. Epub ahead of print 2 November 2022. https:\/\/doi.org\/10.1136\/RMDOPEN-2022-002726","DOI":"10.1136\/RMDOPEN-2022-002726"},{"key":"510_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3899\/jrheum.140101","volume":"91","author":"F Iannone","year":"2014","unstructured":"Iannone F, Cantini F, Lapadula G. Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations. J Rheumatol Suppl. 2014;91:41\u20136.","journal-title":"J Rheumatol Suppl"},{"key":"510_CR29","doi-asserted-by":"publisher","unstructured":"Pettipher C, Benitha R. Tuberculosis in biologic users for rheumatic diseases: results from the South African Biologics Registry (SABIO). Ann Rheum Dis; 79. Epub ahead of print 2020. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2019-216128","DOI":"10.1136\/ANNRHEUMDIS-2019-216128"},{"key":"510_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.24398\/A.438.2022","volume":"58","author":"L Tahiri","year":"2021","unstructured":"Tahiri L, Iraqi G, Bourkadi J, et al. Recommendations of the Moroccan society of rheumatology (SMR) in collaboration with Moroccan pneumophtisiologists for screening and treatment of tuberculosis under biological anti TNF and not anti TNF and under JAK inhibitors during chronic inflammatory rheumatism. Rev Mar Rhum. 2021;58:3\u201318. https:\/\/doi.org\/10.24398\/A.438.2022.","journal-title":"Rev Mar Rhum"},{"key":"510_CR31","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/acr2.11232","volume":"3","author":"J Kremer","year":"2021","unstructured":"Kremer J, Binghamiii cliftono. Postapproval comparative safety study of Tofacitinib and biological Disease-Modifying antirheumatic drugs: 5-Year results from a united States-Based rheumatoid arthritis registry. ACR Open Rheumatol. 2021;3:173\u201384.","journal-title":"ACR Open Rheumatol"},{"key":"510_CR32","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","volume":"177","author":"H Wadstr\u00f6m","year":"2017","unstructured":"Wadstr\u00f6m H, Frisell T, Askling J. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, Tocilizumab, abatacept, or rituximab in clinical practice: A nationwide cohort study from Sweden. JAMA Intern Med. 2017;177:1605\u201312.","journal-title":"JAMA Intern Med"},{"key":"510_CR33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jbspin.2017.08.003","volume":"85","author":"F Atzeni","year":"2018","unstructured":"Atzeni F, Carletto A, Foti R, et al. Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. Joint Bone Spine. 2018;85:455\u20139.","journal-title":"Joint Bone Spine"},{"key":"510_CR34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1136\/annrheumdis-2016-209270","volume":"76","author":"K Hellgren","year":"2017","unstructured":"Hellgren K, Dreyer L, Arkema EV, et al. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers. Ann Rheum Dis. 2017;76:105\u201311.","journal-title":"Ann Rheum Dis"},{"key":"510_CR35","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.rdc.2020.04.001","volume":"46","author":"P Karmacharya","year":"2020","unstructured":"Karmacharya P, Shahukhal R, Ogdie A. Risk of malignancy in spondyloarthritis: A systematic review. Rheum Dis Clin North Am. 2020;46:463\u2013511.","journal-title":"Rheum Dis Clin North Am"},{"key":"510_CR36","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/acr.23781","volume":"71","author":"KL Winthrop","year":"2018","unstructured":"Winthrop KL, Saag K, Cascino MD, et al. Long-Term safety of rituximab in rheumatoid arthritis: analysis from the SUNSTONE registry. Arthritis Care Res (Hoboken). 2018;71:993\u20131003.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"510_CR37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/rheumatology\/key241","volume":"58","author":"KM Fagerli","year":"2019","unstructured":"Fagerli KM, Kearsley-Fleet L, Mercer LK, et al. Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha Inhibition: results from the British society for rheumatology biologics register. Rheumatology (Oxford). 2019;58:80\u20135.","journal-title":"Rheumatology (Oxford)"},{"key":"510_CR38","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1111\/1756-185X.13611","volume":"22","author":"CH Tang","year":"2019","unstructured":"Tang CH, Yu F, Huang CY, et al. Potential benefits of biologics on stroke and mortality in patients with rheumatoid arthritis: A nationwide population-based cohort study in Taiwan. Int J Rheum Dis. 2019;22:1544\u201352.","journal-title":"Int J Rheum Dis"},{"key":"510_CR39","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1136\/ard.2010.129916","volume":"70","author":"JD Greenberg","year":"2011","unstructured":"Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:576\u201382.","journal-title":"Ann Rheum Dis"},{"key":"510_CR40","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1093\/rheumatology\/keac210","volume":"61","author":"AM Kerola","year":"2022","unstructured":"Kerola AM, Kazemi A, Rollefstad S, et al. All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study. Rheumatology (Oxford). 2022;61:4656\u201366.","journal-title":"Rheumatology (Oxford)"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00510-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-025-00510-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00510-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T03:08:56Z","timestamp":1748315336000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-025-00510-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["510"],"URL":"https:\/\/doi.org\/10.1186\/s41927-025-00510-1","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"7 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project was approved by the ethics committee for biomedical research of Faculty of Medicine, Mohammed V. Rabat. Morocco (approval number: A-RS-308\/2017). This study is conducted based on the ethical spirit of the \u201cDeclaration of Helsinki\u201d. All involved participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"N EO and RA: None. IH: Support for meeting attendance from Pfizer, Novartis, Sothema. FA: Lecture honoraria from Pfizer, Abbvie, Bottu, Cooper, Sothema, Support for meeting attendance from Pfizer, Janssen, Participation on a Data Safety Monitoring Board or Advisory Board from Sothema, Pfizer, Abbvie. RB: Lecture honoraria from Pfizer, Abbvie, Bottu, Cooper, Sothema, Janssen, Novartis, Hikma, Newbridge, Support for meeting attendance from Pfizer, Janssen, Newbridge, Cooper, Participation on a Data Safety Monitoring Board or Advisory Board from Sothema, Pfizer, Abbvie. EB I: Lecture honoraria from Pfizer, Abbvie, Bottu, Cooper, janssen, novartis, Support for meeting attendance from Pfizer, Janssen, abbvie, hikma, sothema. I EG: Lecture honoraria from Pfizer, Abbvie, Novartis, Sothema, Cooper, Support for meeting attendance from Pfizer, Roche, Participation on a Data Safety Monitoring Board or Advisory Board from Sothema, Pfizer, Janssen, NewBridge Pharmaceuticals. HH: Lecture honoraria from Pfizer, Abbvie, Novartis, Sothema, Cooper, Support for meeting attendance from Pfizer, Roche, Participation on a Data Safety Monitoring Board or Advisory Board from Sothema, Pfizer, Janssen, NewBridge Pharmaceuticals. LI: Lecture honoraria from Pfizer, Bottu, Phi. SJ: None. HT: Lecture honoraria from Abbvie, Bottu, Sothema, Janssen, Support for meeting attendance from Pfizer, Sothema, Participation on a Data Safety Monitoring Board or Advisory Board from Sothema, Pfizer, NewBridge pharmaceuticals, Abbvie, Novartis. RN: Lecture honoraria from Pfizer, Abbvie, Bottu, Jenssen, Sothema, Support for meeting attendance from Pfizer, Janssen, Roche, Participation on a Data Safety Monitoring Board or Advisory Board from Pfizer, Abbvie, Jenssen, Sothema, NewBridge. AB:: Lecture honoraria from Pfizer, Abbvie, Bottu, Cooper, Sothema, Support for meeting attendance from Pfizer, Janssen, Participation on a Data Safety Monitoring Board or Advisory Board from Sothema, Pfizer, Abbvie. A EM: Lecture honoraria from Pfizer, Abbvie, Bottu, Cooper, Sothema, Support for meeting attendance from Pfizer, Janssen, Participation on a Data Safety Monitoring Board or Advisory Board from Sothema, Pfizer, Abbvie.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}